Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246

162Citations
Citations of this article
97Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

ST-246, a potent orthopoxvirus egress inhibitor, is safe and effective at preventing disease and death in studies of small-animal models involving challenge by several different pathogenic poxviruses. In this report, the antiviral efficacy of ST-246 in treatment of nonhuman primates infected with variola virus or monkeypox virus was assessed. The data indicate that oral dosing once per day with ST-246 protects animals from poxvirus disease, as measured by reductions in viral load and numbers of lesions and enhancement of survival. Copyright © 2009, American Society for Microbiology. All Rights Reserved.

Cite

CITATION STYLE

APA

Huggins, J., Goff, A., Hensley, L., Mucker, E., Shamblin, J., Wlazlowski, C., … Hruby, D. (2009). Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246. Antimicrobial Agents and Chemotherapy, 53(6), 2620–2625. https://doi.org/10.1128/AAC.00021-09

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free